The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab
Maureen Trudeau1, Brent Fraser2
1Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
Current Oncology (Toronto, Ont.)
|May 26, 2023
Abstract:
CADTH read with interest the commentary published on 16 December 2022, entitled "Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain" [...].


